Our Website Uses Cookies
We and the third parties that provide content, functionality, or business services on our website may use cookies to collect information about your browsing activities in order to provide you with more relevant content and promotional materials, on and off the website, and help us understand your interests and improve the website.
For more information, please contact us or consult our Privacy Notice.
Your binder contains too many pages, the maximum is 40.
We are unable to add this page to your binder, please try again later.
This page has been added to your binder.
Brexit Immigration Update
January 18, 2017, Covington Alert
The British Prime Minister, Theresa May, has now confirmed the government’s view that the United Kingdom must leave the European single market in order to give effect to the outcome of the EU referendum held on June 23, 2016. In light of that statement, the UK government’s promise to guarantee the status of EEA nationals already residing in the UK as soon as possible after commencement of negotiations will provide little comfort to those affected. Prime Minister May made it clear that UK rights and protections will depend on UK nationals residing in other Member States receiving the same rights and protections, which may take months, even years, to agree.
June 27, 2020
WASHINGTON—Covington represented Piramal Enterprises Limited (PEL) in the sale of a 20% stake in Piramal Pharma Limited (Piramal Pharma), a wholly owned subsidiary of PEL that will contain its pharmaceutical businesses, to CA Clover Intermediate II Investments, an affiliated entity of CAP V Mauritius Limited, an investment fund managed and advised by affiliated ...
Spring 2020, Covington Guide
As businesses across Europe prepare to reopen following the COVID-19 lockdown, Covington is providing practical resources and guidance on the broad array of issues companies face as employees return to the workplace, including employment, privacy, competition, policy, environmental and regulatory considerations at the EU level, with a focus on Germany and the ...
Covington Advises Ziylo on Acquisition by Novo Nordisk
August 23, 2018
LONDON—Covington has advised Ziylo on its acquisition by Novo Nordisk with a potential deal value that could exceed $800 million. Ziylo, a University of Bristol spin-out company based at the Unit DX science incubator, is a supramolecular chemistry company that has developed a third 'biomimetic' class of glucose binding molecules. The acquisition gives Novo ...